Overview
Good Pharmacovigilance Practice (GVP) Training is the essential foundation for professionals responsible for monitoring the safety of pharmaceutical products throughout their lifecycle. Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems . This guide provides a comprehensive overview of GVP training requirements and the programs available to help you stay compliant with global regulatory standards.
The Importance of GVP Training in Drug Safety
GVP Training is critical for ensuring the ongoing safety of pharmaceutical products after they reach the market. Key reasons why GVP training is essential include:
- Protecting Patient Safety – identifying and managing risks associated with drug use
- Ensuring Regulatory Compliance – meeting requirements of FDA, EMA, Health Canada, and other agencies
- Maintaining Public Trust – demonstrating commitment to drug safety and transparency
- Supporting Risk Management – implementing effective pharmacovigilance systems
- Facilitating Global Drug Safety – enabling consistent safety monitoring across jurisdictions
Key Regulatory Frameworks Covered in GVP Training
Comprehensive GVP Training covers multiple regulatory frameworks, including:
- ICH E2 Series – E2A (Clinical Safety Data Management), E2B(R3) (ICSR Data Elements), E2C(R2) (Periodic Benefit-Risk Evaluation Report), E2D (Post-Approval Safety Data), E2E (Pharmacovigilance Planning), and E2F (Development Safety Update Report)
- EU GVP Modules – European Medicines Agency guidelines for pharmacovigilance systems
- FDA Regulations – 21 CFR Parts 312 and 314 for adverse event reporting
- Canadian GVP Guidelines – Health Canada requirements for drug safety monitoring
Detailed Course Breakdown
Course 1: Global Pharmacovigilance and Safety Reporting
This training program provides a comprehensive and detailed understanding of global regulatory requirements for pharmacovigilance, including adverse event reporting, signal detection, risk management, and periodic safety reporting.
Scope: The program integrates requirements from major regulatory bodies, including the FDA (21 CFR Parts 312 and 314), ICH guidelines (E2A, E2B(R3), E2C(R2), E2D(R1), E2E, E2F), EU GVP modules, Canadian GVP guidelines, and MedDRA coding standards.
Description of Modules: The curriculum covers 10 comprehensive sections:
- Introduction to Pharmacovigilance and its importance in drug safety
- Adverse Event Reporting – definitions and classifications
- Expedited Reporting – 7-day and 15-day reporting requirements
- Periodic Safety Reports – PSURs, PBRERs, and DSURs
- Signal Detection and risk management planning
- MedDRA Coding and Standardised MedDRA Queries (SMQs)
- Pharmacovigilance System establishment and maintenance
- Risk Management Plans and risk minimization measures
- Global Regulatory Requirements across jurisdictions
- Case Studies and practical application scenarios
Target Audience:
- Pharmacovigilance and Drug Safety Professionals
- Clinical Research Associates and Clinical Trial Monitors
- Regulatory Affairs Specialists
- Quality Assurance Personnel in Pharmaceutical Companies
- Medical Affairs Professionals
- Contract Research Organization (CRO) Staff
- Marketing Authorization Holders (MAHs) and their representatives
Pricing: $349.00 with group discounts available.
FAQ:
- What is the difference between a GVP and a GCP? GCP (Good Clinical Practice) focuses on the conduct of clinical trials, while GVP (Good Pharmacovigilance Practice) focuses on the monitoring of drug safety throughout the product lifecycle.
- What is an adverse event (AE) vs. an adverse drug reaction (ADR)? An adverse event is any untoward medical occurrence in a patient, while an adverse drug reaction is a causal relationship between the drug and the event is at least a reasonable possibility.
- What is the difference between a 7-day and 15-day safety report? A 7-day alert report is required for fatal or life-threatening unexpected serious adverse reactions, while a 15-day report is required for all other unexpected serious adverse reactions.
- What is MedDRA and why is it important? MedDRA (Medical Dictionary for Regulatory Activities) is the international standard for coding adverse events, enabling consistent safety data exchange globally.
- What is a PBRER? A PBRER (Periodic Benefit-Risk Evaluation Report) is a comprehensive safety report submitted at regular intervals after drug approval.
Enroll Now: https://www.gxptrainings.com/courses/global-pharmacovigilance-and-safety-reporting/
Course 2: Certified Regulatory Affairs Professional (CRAP)
This comprehensive certification program provides regulatory professionals with end-to-end knowledge of the global pharmaceutical regulatory landscape, including critical pharmacovigilance requirements.
Scope: The program covers the complete drug development lifecycle from discovery through post-approval lifecycle management, with specific focus on the regulatory requirements of the United States (FDA), European Union (EMA), and Japan (PMDA), as well as harmonization initiatives under ICH. It includes comprehensive coverage of pharmacovigilance regulations, safety reporting, and post-marketing requirements.
Description of Modules: The curriculum covers 10 comprehensive sections:
- Global Regulatory Framework overview
- Investigational New Drug (IND) applications
- New Drug Applications (NDA) for innovative pharmaceuticals
- Abbreviated New Drug Applications (ANDA) for generics
- Biologics License Applications (BLA) for biological products
- Orphan Drug Designation for rare disease treatments
- Special Programs including Accelerated Approval and Breakthrough Therapy
- Pharmacovigilance and Post-Marketing Requirements
- Regulatory Agency Interactions and meeting management
- Global Regulatory Strategy development
Target Audience:
- Regulatory Affairs Professionals
- Pharmacovigilance and Drug Safety Professionals
- Pharmaceutical Development and Formulation Scientists
- Quality Assurance/Quality Control Professionals
- Clinical and Nonclinical Development Professionals
- CMC Specialists and Manufacturing Personnel
- Project Management Professionals
- CRO and CMO Personnel
- Legal and Intellectual Property Professionals
Pricing: $799.00 with group discounts available.
FAQ:
- How does regulatory affairs training support GVP? Understanding the full drug development lifecycle helps pharmacovigilance professionals integrate safety considerations into regulatory strategy.
- What is the role of pharmacovigilance in the drug lifecycle? Pharmacovigilance ensures ongoing safety monitoring from clinical trials through post-approval marketing.
- What is a Risk Management Plan (RMP)? An RMP is a document describing the pharmacovigilance activities and risk minimization measures for a drug.
- What are the key elements of a Pharmacovigilance System Master File (PSMF)? The PSMF describes the pharmacovigilance system, including processes, responsibilities, and documentation.
- How does regulatory affairs integrate with pharmacovigilance? Regulatory affairs professionals ensure that safety data is submitted to regulatory authorities in compliance with requirements.
Enroll Now: https://www.gxptrainings.com/courses/certified-regulatory-affairs-professional/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Authors
